Kuwait Pharmaceuticals & Healthcare Report Q3 2014 - New Study Released

Despite upcoming by-elections , Kuwait's economy is forecast to post moderate growth in 2014, and the prospects for consumption remain bright. While price harmonisation across the GCC is likely to have a significant impact on margins in the sector, implementation remains slow. Concern over fake generic drugs presents opportunities for the segment in the country , and has spurred partnership agreements with local distributors in the region. Healthcare spending will remain strained as the government continues to legislate populist measures targeting expatriate workers and visitors.

Headline Expenditure Projections

* Pharmaceuticals: KWD290mn (USD1.02bn) in 2013 to KWD306mn (USD1.10bn) in 2014; +5.6% in local currency terms and +7.6% in US dollar terms. Forecast upwardly revised raised in USD terms for 2014.
* Healthcare: KWD1.43bn (USD5.03bn) in 2013 to KWD1.56bn (USD5.58bn) in 2014; +8.8% in local currency terms and +10.8% in US dollar terms. Forecast lowered in USD terms for 2014.

Full Report Details at
- http://www.fastmr.com/prod/852054_kuwait_pharmaceuticals_healthcare_report_q3_2014.aspx?afid=301

Risk/Reward Rating

Kuwait scored 58.5 in BMI's Pharmaceutical Risk/Reward Rating (RRR) for Q314 - unchanged from the previous quarter. Kuwait stands at second place, behind Saudi Arabia, out of a total of 30 markets.

Key Trends And Developments

In May 2014, the Kuwaiti parliament was considering proposals to introduce compulsory health insurance for visitors to the country. This follows a proposal for stricter healthcare checks and eye check-ups for incoming expatriates in the same month.

In May 2014, MSD, the international operations arm of Merck, signed an agreement with UAE-based Gulf Pharmaceutical Industries to produce, market, distribute and sell certain MSD products in Kuwait, the UAE, Bahrain, Oman, Qatar and Iraq.

In April 2014, GSK announced that it is conducting investigations into company practices in Kuwait among other countries in the Middle East. This follows anti-bribery investigations into the company's practices in China.

In April 2014,...

The Kuwait Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Kuwait Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Kuwaiti pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Kuwait to test other views - a key input for successful budgeting and strategic business planning in the Kuwaiti pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Egypt Pharmaceuticals & Healthcare Report Q3 2014
- Malaysia Pharmaceuticals & Healthcare Report Q3 2014
- Moldova Pharmaceuticals & Healthcare Report Q3 2014
- Peru Pharmaceuticals & Healthcare Report Q3 2014
- France Pharmaceuticals & Healthcare Report Q3 2014